Probiomic Therapeutics™ for Eczema, Atopic Dermatitis, Eosinophilic Esophagitis (EoE), Metabolic Disorders
Wed, 21/09/2016 - 14:00
Wed, 21/09/2016 - 10:45
Leiden, The Netherlands, and Woburn, MA, 21st September 2016 / Sciad Newswire / Batavia Biosciences received an $8 million grant from the Bill &a
Mon, 12/09/2016 - 09:30
Saffron Walden, UK, 12th September 2016 / Sciad Newswire / Established in 2001, Domainex is a privately-owned, rapidly-growing drug research company with expertis
Mon, 25/07/2016 - 08:00
Prokarium announces funding from UK & Mexican Governments to develop vaccines against Zika, bacterial diarrhoea and Plague.
Wed, 13/07/2016 - 15:00
Cypralis, a life sciences company focussed on the discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases (PPIases) has acquired a portfolio of cyclophilin inhibitor assets from SCYNEXIS Inc, a NASDAQ-listed company headquartered in New Jersey, USA.
Mon, 11/07/2016 - 16:00
Pearson Medical Technologies, a leader in pharmacy automation solutions, will showcase at RBC Cardinal 2016 in Chicago, IL from July 20-23 with XchangeLabs.
Thu, 09/06/2016 - 13:45
Advanced cell-line technology could reduce costs of vaccine production.
Wed, 25/05/2016 - 09:00
Selcia opens new state-of-the-art API radiolabelling laboratory.
Thu, 05/05/2016 - 09:00
Mercia has committed follow-on capital to Medherant Ltd. Medherant’s patch, known as the TEPI-patch®, is a thin, strong, easy-to-apply and easy-to-remove patch capable of delivering higher doses of drugs.
Tue, 26/04/2016 - 09:00
Queen’s University Belfast and Domainex Ltd secure funding from the Wellcome Trust to accelerate early development of first-in-class FLIP inhibitors.